Sign In
Learn bits
Health & Medicine
Mahesh

02/11/23 09:30 AM IST

India’s own CAR-T cell therapy

In News
  • The Central Drugs Standard Control Organisation (CDSCO) this month granted market authorisation for NexCAR19, India’s first indigenously-developed CAR-T cell therapy, to ImmunoACT, a company incubated by IIT Bombay.
CAR-T cell therapy
  • CAR-T is a revolutionary therapy that modifies immune cells, specifically T-cells, by turning them into potent cancer fighters known as CAR-T cells.
  • T-cells are special cells (white blood cells that find and fight illness and infection) whose primary function is cytotoxic, meaning it can kill other cells. In CAR-T therapy, we genetically modify them into cancer-fighting cells.
  • These supercharged cells are then put back into the body, and they go after cancer cells — especially in blood cancers like leukaemia and lymphomas.
  • While chemotherapy and immunotherapy may add a few months or years to a cancer patient’s life, cell-and-gene therapy is designed to cure and provide lifelong benefit.
  • It makes treatment easier with a one-time therapy [unlike several sessions of chemotherapy] that can be truly transformative [for a patient]. It’s a lifeline for non-responsive cancer patients.
NexCar19
  • NexCar19 is a type of CAR-T and gene therapy developed indigenously in India by ImmunoACT, which is a company incubated at IIT Bombay.
  • Our therapy is designed to target cancer cells that carry the CD19 protein.
  • This protein acts like a flag on cancer cells, which allows CAR-T cells to recognise and attach themselves to the cancer cells and start the process of elimination.
  • Even some developed nations don’t have their own CAR-T therapies; they import them from the United States or Europe.
  • India is now one of the first developing countries to have its indigenous CAR-T and gene therapy platform.
Who can get benefit from NexCar19 therapy?
  • The therapy is for people with B-cell lymphomas who didn’t respond to standard treatments like chemotherapy, leading to relapse or recurrence of the cancer.
  • The patient’s journey starts with a doctor’s prescription at the clinic, followed by donation of blood by the patient at a transfusion centre.
  • The blood goes to the lab, where the T-cells are genetically modified.
  • In a week to 10 days, these cells return to the clinic for patient reinfusion.
  • Essentially, patients only need to give a blood sample at their clinic, and come back in 7-10 days for reinfusion.
  • Recovery typically occurs within two weeks after one cycle of the treatment.
  • In our data, approximately 70% of patients respond to the treatment, with variations between leukaemia and lymphoma cases.
  • About 50% of these responsive patients achieve a complete response.
Cost pf the therapy
  • Currently, we are looking at a price range of Rs 30-40 lakh for CAR-T therapy, which we intend to hold. Even at this cost, it may not be accessible to everyone.
  • Our ultimate goal is to bring the cost down to Rs 10-20 lakh.
  • As technology matures and manufacturing processes improve, we anticipate that the cost will decrease.
Source- Indian Express

More Related Current Affairs View All

13 Aug

Working of satellite internet

'Satellite internet is revolutionizing how we connect, extending high-speed access to virtually every corner of the globe, regardless of location.' Imagine getting online from t

Read More

13 Aug

CBSE’s plan for open-book exams

'The Central Board of Secondary Education (CBSE) has officially approved the introduction of Open-Book Assessments (OBAs) for Class 9 students starting from the 2026-27 academic se

Read More

12 Aug

Stray dog problem

'The Supreme Court  directed the Delhi government, civic bodies, and authorities of Noida, Gurgaon, and Ghaziabad to round up and move stray dogs to shelters, underlining the

Read More

India’s First Ai-Driven Magazine Generator

Generate Your Custom Current Affairs Magazine using our AI in just 3 steps